List of Excipients in Branded Drug NORITATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	NORITATE	metronidazole	0187-5202	GLYCERIN
Bausch Health US LLC	NORITATE	metronidazole	0187-5202	GLYCERYL MONOSTEARATE
Bausch Health US LLC	NORITATE	metronidazole	0187-5202	METHYLPARABEN
Bausch Health US LLC	NORITATE	metronidazole	0187-5202	PROPYLPARABEN
Bausch Health US LLC	NORITATE	metronidazole	0187-5202	STEARIC ACID
Bausch Health US LLC	NORITATE	metronidazole	0187-5202	TROLAMINE

Noritate Excipient Strategy and Commercial Opportunities for Metronidazole 1% Cream

Last updated: October 3, 2026

Noritate is a topical metronidazole 1% cream indicated for the inflammatory lesions of rosacea. Its commercial value is no longer driven by new-drug exclusivity. Opportunity lies in improving tolerability, sensory properties, preservative systems, packaging, manufacturing efficiency, and differentiated topical delivery while maintaining pharmaceutical equivalence or supporting a 505(b)(2) strategy.[1]

The current formulation uses a conventional oil-in-water cream with fatty alcohols, glyceryl stearate, PEG 100 stearate, isopropyl myristate, propylene glycol, benzyl alcohol, methylparaben, and purified water.[2]

What excipients are used in Noritate cream?

Noritate contains metronidazole at 1% as the active pharmaceutical ingredient. The FDA labeling identifies the following inactive ingredients:[2]

Excipient	Primary function	Commercial or technical relevance
Purified water	Continuous aqueous phase	Controls viscosity, microbial risk, and processing
Glyceryl stearate	Emulsifier and consistency agent	Supports cream structure and skin feel
PEG 100 stearate	Nonionic emulsifier	Stabilizes the oil-in-water emulsion
Cetyl alcohol	Fatty alcohol, thickener, co-emulsifier	Improves viscosity and emolliency
Stearyl alcohol	Fatty alcohol, thickener, co-emulsifier	Supports body, stability, and application feel
Isopropyl myristate	Emollient and penetration-supporting vehicle	Influences spreadability and residue
Propylene glycol	Humectant and cosolvent	Supports hydration and metronidazole distribution
Benzyl alcohol	Preservative and solvent	Contributes to microbial protection but may raise irritation concerns
Methylparaben	Preservative	Provides antifungal and antibacterial preservation

The formulation is technically familiar and uses widely available excipients. This lowers manufacturing complexity but also limits product differentiation based solely on composition.

How does the Noritate formulation work?

Noritate is an oil-in-water emulsion. The dispersed oil phase provides emolliency and skin feel, while the aqueous phase supports spreadability and drug release. The combination of glyceryl stearate and PEG 100 stearate provides the principal emulsification system. Cetyl and stearyl alcohol increase viscosity and improve the cream’s consistency.

Isopropyl myristate is commercially important because it produces a lighter, more spreadable product than a highly waxy base. It can also alter drug partitioning between the formulation and the stratum corneum. Propylene glycol provides humectancy and may improve metronidazole solubilization, although its concentration must be controlled because higher levels can cause stinging or irritation in sensitive skin.

The main formulation risks are:

1. Preservative-related irritation from benzyl alcohol or methylparaben.
2. Sensory variability caused by fatty alcohol ratios.
3. Phase separation during temperature cycling.
4. Drug crystallization or nonuniform metronidazole distribution.
5. Differences in release and skin permeation relative to the reference product.

What commercial opportunities exist for Noritate excipient reformulation?

The strongest opportunities are products that preserve metronidazole 1% efficacy while addressing tolerability, cosmetic acceptability, and adherence.

Low-irritation preservative systems

A reformulated product could replace or reduce benzyl alcohol and methylparaben through:

• Phenoxyethanol-based preservation.
• Organic acid systems such as benzoic acid or sorbic acid.
• Caprylyl glycol or glyceryl caprylate combinations.
• Chelator-supported preservation systems.
• Low-water or anhydrous formats.

Each alternative requires preservative efficacy testing, compatibility studies, packaging assessment, and comparative drug-product performance testing. A preservative-free formulation could be commercially attractive for patients with sensitive or reactive skin, but it would require a robust microbiological control strategy.

Fragrance-free and low-sensitizer positioning

Rosacea patients often avoid products associated with burning, stinging, fragrance, or heavy occlusion. Noritate already uses a relatively conventional dermatological cream base, but a differentiated product could emphasize:

• Fragrance-free composition.
• Reduced volatile or aromatic excipients.
• Lower propylene glycol exposure.
• Reduced surfactant load.
• Minimal-irritant preservative system.
• Clinically measured tolerability.

These claims would require substantiation and careful regulatory wording. "Sensitive skin" positioning is more commercially credible when supported by tolerability studies rather than ingredient marketing alone.

Improved cosmetic elegance

Many topical dermatology products underperform because patients dislike residue, greasiness, pilling, or slow absorption. A new metronidazole cream could target:

• Faster rub-in.
• Lower tack.
• Reduced whitening.
• Improved compatibility with sunscreen or cosmetics.
• Lower transfer to clothing.
• Better application over large facial areas.

Potential tools include lighter emollients, optimized ester blends, lamellar emulsions, silicone-compatible systems, and controlled fatty alcohol ratios. These changes can improve adherence without changing the metronidazole dose.

Airless and unit-dose packaging

Packaging is a practical source of differentiation. Airless pumps can reduce repeated environmental exposure and limit contamination during use. They can also support a preservative-reduced formulation, although the package does not eliminate the need for microbiological testing.

Unit-dose sachets or small single-use packages could support:

• Samples and physician detailing.
• Travel use.
• Controlled dosing.
• Reduced contamination.
• Specialty pharmacy distribution.

The disadvantages are higher packaging cost, more material waste, and possible dose variability if the patient does not use the full unit.

What formulation patents could protect a new Noritate product?

A patent on metronidazole alone would provide little strategic value because the active ingredient and basic topical uses are old. Protectable subject matter would need to focus on a specific formulation, manufacturing process, delivery system, or clinical performance.

Potential patent categories include:

Patent category	Example claim focus	Relative commercial value
Excipient composition	Defined emulsifier, emollient, preservative, or solvent ranges	Moderate if performance is unexpected
Low-irritation formulation	Reduced stinging or improved tolerability supported by data	Moderate to high
Drug-release profile	Specific in vitro release or skin-deposition characteristics	Moderate
Anhydrous or low-water formulation	Improved stability or preservative reduction	Moderate
Packaging and dispensing	Airless system or metered-dose delivery	Low to moderate
Manufacturing process	Homogenization, temperature, or order-of-addition controls	Moderate if difficult to reproduce
Combination therapy	Metronidazole with another active ingredient	Potentially high, depending on clinical differentiation
Method of use	Specific rosacea population, regimen, or sequencing	Variable and often vulnerable to design-around

A formulation patent would be stronger if it linked the excipient selection to a measurable technical result, such as improved metronidazole uniformity, reduced degradation, superior release, lower irritation, or longer shelf life. A list of conventional excipients at routine concentrations would face a higher obviousness risk.

When does Noritate lose exclusivity?

Noritate does not have the commercial profile of a recently approved new molecular entity. Metronidazole is an established active ingredient, and the relevant product has been marketed for many years. The primary commercial barriers are therefore formulation approval, manufacturing capability, physician prescribing behavior, branding, and reimbursement rather than NCE exclusivity.

The FDA Orange Book should be used to confirm current patent listings, exclusivity codes, reference-listed-drug status, and any product-specific regulatory entries.[3] FDA’s Drugs@FDA database is the controlling source for the application record and approval history.[4]

A generic company would normally pursue an ANDA if it can demonstrate pharmaceutical equivalence and meet the applicable requirements for topical dermatological products. A materially different formulation, delivery system, or clinical use may instead require a 505(b)(2) application.

What is the Orange Book status of Noritate?

Noritate’s commercial protection should be analyzed through four separate questions:

1. Is the product listed as a reference listed drug?
2. Are current patents listed against the relevant NDA?
3. Is any regulatory exclusivity still active?
4. Can a competing product qualify for an ANDA rather than a 505(b)(2) application?

The age of the product means any historic patents or exclusivity periods are unlikely to provide durable protection by themselves. Current value depends on whether a listed patent remains enforceable and relevant to the proposed generic product.

An applicant should distinguish Noritate cream 1% from other metronidazole products, including:

• Metronidazole gel 0.75%.
• Metronidazole topical gel 1%.
• Metronidazole lotion.
• Metronidazole vaginal products.
• Oral metronidazole tablets and capsules.

These dosage forms are not automatically substitutable. A generic cream must match the reference product’s dosage form, strength, route, and relevant pharmaceutical characteristics.

What Paragraph IV risks exist for Noritate?

If an applicant files an ANDA referencing Noritate and certifies that a listed patent is invalid, unenforceable, or will not be infringed, the filing may include a Paragraph IV certification under the Hatch-Waxman framework.[5]

For a legacy topical product, the main Paragraph IV risks are:

• A patent owner files infringement litigation within the statutory period.
• FDA approval is subject to a 30-month stay, where applicable.
• The patent owner asserts formulation or method-of-use claims.
• The applicant must carve out a patented indication or instruction.
• The court upholds a formulation patent despite the active ingredient’s age.

The commercial threat from litigation may be limited when patents are expired, weak, poorly listed, or easy to design around. The risk becomes more material if the listed claims cover a specific cream composition or a narrow delivery feature that the proposed generic must reproduce.

How strong is the patent estate for Noritate?

The underlying metronidazole estate is weak as a source of exclusivity because the molecule and basic antibacterial and antiprotozoal uses are longstanding. The potential strength of a modern estate would come from secondary patents.

Stronger patent positions

A stronger position would generally include:

• Narrow but reproducible composition claims.
• Evidence of unexpected stability or tolerability.
• Claims tied to a specific manufacturing process.
• Demonstrated superiority in skin deposition or release.
• A formulation that is difficult to reproduce without practicing the claims.

Weaker patent positions

A weaker position would generally include:

• Broad claims covering conventional oil-in-water creams.
• Routine excipient substitutions.
• Functional claims without validated testing.
• Method-of-use claims that merely restate the labeled rosacea indication.
• Claims dependent on excipient concentrations commonly used in topical products.

Patent strength must be assessed against the actual claims, prosecution history, file-wrapper estoppel, prior art, and listed status. The product label alone cannot establish enforceable patent protection.

What FDA regulatory pathway applies to a new Noritate competitor?

ANDA pathway

An ANDA is the lowest-cost route when the product can demonstrate pharmaceutical equivalence to the reference product and satisfy FDA requirements for topical product equivalence. The applicant must address:

• Same active ingredient.
• Same strength.
• Same dosage form.
• Same route of administration.
• Equivalent inactive-ingredient safety.
• Product quality and stability.
• Comparative performance, including applicable topical bioequivalence requirements.

FDA’s guidance for topical dermatological products emphasizes product quality, formulation sameness or similarity, and comparative performance testing. The precise evidence package depends on the dosage form and FDA’s product-specific guidance.[6]

505(b)(2) pathway

A 505(b)(2) application may be appropriate for:

• A materially different vehicle.
• A new delivery system.
• A preservative-free or anhydrous product.
• A new dosage regimen.
• A clinically differentiated combination.
• A formulation supported partly by published literature or FDA findings for metronidazole.

The 505(b)(2) route can create a more defensible commercial position but usually involves greater development cost and clinical or comparative evidence.

Which commercial strategies are most attractive?

Strategy	Regulatory route	Differentiation	Development risk	Commercial outlook
Conventional generic cream	ANDA	Low	Moderate	Price-driven
Low-irritation generic	ANDA or 505(b)(2)	Moderate	Moderate to high	Better payer and patient positioning
Preservative-reduced cream	505(b)(2) or specialized ANDA strategy	High	High	Premium potential
Airless-pump cream	ANDA or 505(b)(2)	Moderate	Moderate	Supports adherence and contamination control
Cosmetic-elegant cream	ANDA or 505(b)(2)	Moderate	Moderate	Strong direct-to-consumer potential
Metronidazole combination product	505(b)(2) or new application	High	High	Potentially stronger pricing
Compounded or specialty pharmacy product	State and federal compounding framework	Moderate	Lower development cost	Limited scale and weaker exclusivity

The most practical opportunity is a metronidazole 1% cream with improved sensory properties, reduced irritation potential, and packaging that supports clean dosing. A product claiming clinical superiority would require substantially more evidence.

What manufacturing and IP barriers affect entry?

The manufacturing process is not inherently difficult, but reproducibility matters. Key controls include:

• Order of excipient addition.
• Emulsification temperature.
• Homogenization intensity.
• Cooling rate.
• Metronidazole particle-size distribution.
• pH control.
• Filling temperature.
• Container-closure compatibility.

Scale-up can change droplet size, viscosity, drug distribution, and release. Those differences can affect regulatory comparability even when the qualitative composition appears similar.

Manufacturing know-how may provide practical protection where patent protection is limited. A producer with validated scale-up data, stable supply agreements, and a reliable preservative system can reach the market faster than a nominally equivalent competitor.

How does Noritate compare with other metronidazole topical products?

Product type	Typical strength	Dosage form	Main commercial distinction
Noritate	1%	Cream	Emollient vehicle for facial rosacea use
Metronidazole gel	0.75% or 1%	Gel	Lighter sensory profile and faster drying
Metronidazole lotion	Varies	Lotion	Easier spread over larger areas
Oral metronidazole	Systemic dose	Tablet or capsule	Systemic exposure and different safety profile

Creams can appeal to patients with dry or sensitive skin, while gels and lotions may be preferred by patients seeking a lighter finish. The formulation opportunity is to retain the barrier-supporting properties of a cream without the residue and tack associated with older emulsion systems.

Key Takeaways

• Noritate is a metronidazole 1% topical cream for rosacea.
• Its excipient system is a conventional oil-in-water emulsion based on fatty alcohols, glyceryl stearate, PEG 100 stearate, isopropyl myristate, propylene glycol, benzyl alcohol, and methylparaben.
• The strongest commercial opportunities involve tolerability, cosmetic elegance, preservative reduction, and airless packaging.
• The active ingredient offers limited exclusivity value because metronidazole is an established drug.
• Secondary formulation patents require evidence of a specific technical advantage, not merely a conventional excipient combination.
• A conventional competitor would likely target the ANDA route; materially differentiated products may require 505(b)(2) development.
• Generic entry risk is principally regulatory and commercial rather than molecule-level patent risk.
• Manufacturing controls and formulation know-how can be more valuable than broad composition claims.

FAQs

Can a metronidazole 1% cream use different excipients from Noritate?

Yes, provided the product satisfies FDA requirements for safety, quality, pharmaceutical equivalence, and topical bioequivalence. An excipient change can affect drug release, skin penetration, preservation, viscosity, and regulatory classification.

Is Noritate interchangeable with metronidazole gel?

No. Cream and gel products differ in dosage form, excipient composition, sensory properties, and potentially their performance on skin. Substitution depends on the approved product labeling and applicable pharmacy rules.

Could a preservative-free Noritate alternative obtain premium pricing?

Potentially. A preservative-reduced or preservative-free product could target patients with sensitive skin, but premium pricing would require credible tolerability, packaging, stability, and reimbursement support.

Are formulation patents the main barrier to generic Noritate entry?

Usually not. For an older topical drug, the main barriers are product development, comparative performance testing, manufacturing scale-up, FDA review, distribution, and payer access. A valid listed formulation patent could change that assessment.

What is the most defensible new product concept based on Noritate?

A metronidazole 1% cream with a low-irritation excipient system, improved cosmetic feel, validated stability, and metered airless dispensing offers the clearest balance between technical differentiation and commercial feasibility.

References

1. U.S. Food and Drug Administration. (n.d.). Noritate (metronidazole) cream, 1%: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
2. U.S. National Library of Medicine. (n.d.). Noritate-metronidazole cream: Inactive ingredients and labeling. DailyMed. https://dailymed.nlm.nih.gov/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
5. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
6. U.S. Food and Drug Administration. (2022). Guidance for industry: Acyclovir cream, metronidazole gel, and other topical dermatological drug products: Product-specific recommendations and bioequivalence considerations. https://www.fda.gov/drugs/development-resources/ li